Comparing apremilast and methotrexate for moderate to severe plaque psoriasis
Compares apremilast with methotrexate in adults with chronic plaque psoriasis.
Plain-language title generated from the registry record
Registry title: To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital
Key facts
- Where
- Peshawar, PakistanSee the site
- Phase
- Early phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 60 with moderate to severe plaque psoriasis who have not had systemic treatment in the past 3 months.
- Age
- 18 to 60 years
- Sex
- Women and men can both join.
- Disease stage
- Moderate to severe plaque psoriasis (PASI ≥10).
- Earlier treatment
- No systemic therapy in the past 3 months.
Main reasons for not taking part
- Pregnancy or breastfeeding
- History of liver or kidney dysfunction
- Known hypersensitivity to the study drugs
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07337434, who can take part
Where in Pakistan
- MTI-HMC PeshawarPeshawar, PakistanContact: Filza Ajmal, FCPS part 2Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Syeda Sana Zaman
- Trial code
- NCT07337434
- Record updated
- 13 January 2026
- Original description
This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly in Peshawer,this study will provide valuable insights into optimal treatment strategies.Read full original descriptionShow less
Comparison of Efficacy of Methotrexate vs Apremilast in Moderate to Severe Plaque Psoriasis
This study aims to compare efficacy of methotrexate vs apremilast in the management of chronic plaque psoriasis.Given the high prevalence of psoriasis in Pakistan and the significant psychological impact on patients, particularly in Peshawer,this study will provide valuable insights into optimal treatment strategies.
Inclusion: Patients having age between 18-60 years of either gender Diagnosed with moderate to severe plaque psoriasis (PASI ≥10) No prior systemic therapy in past 3 months.
Exclusion: Pregnancy or lactation History of liver or renal dysfunction Known hypersensitivity to study drugs.